https://websites4-live-prod.ysmdevs.com/lab/schalper/news-rss/?orgId=115902&title=Latest+News A selection of the latest research, academic, and other newsworthy developments at Schalper Lab en-us Copyright 2026 Yale School of Medicine Thu, 14 May 2026 20:14:23 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/twenty-seven-ysm-faculty-members-recognized-for-highly-cited-research/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/twenty-seven-ysm-faculty-members-recognized-for-highly-cited-research/ Yale School of Medicine faculty members were recognized for publishing studies that rank in the top 1% based on the number of citations they received in their field. Wed, 12 Nov 2025 08:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/google-maps-approach-to-revolutionize-lung-cancer-treatment/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/google-maps-approach-to-revolutionize-lung-cancer-treatment/ Researchers, led by Thazin Nwe Aung, PhD, in the laboratory of David Rimm, MD, PhD, have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with the most common form of lung cancer to receive more effective individualized treatment. Fri, 10 Oct 2025 04:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/yale-cancer-center-experts-to-present-at-top-international-oncology-conference/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/yale-cancer-center-experts-to-present-at-top-international-oncology-conference/ Later this week, at the 2025 ESMO Congress in Madrid, Spain, YCC researchers will deliver oral presentations, participate in panel discussions, and lead educational sessions covering a wide range of topics, including targeted therapies, biomarkers for resistance to immunotherapy, innovative combination therapies for advanced colorectal cancer, and advancements in patient supportive care. Wed, 08 Oct 2025 04:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/rimm-lab-marks-30-years-of-research-innovation-training-at-yale-pathology/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/rimm-lab-marks-30-years-of-research-innovation-training-at-yale-pathology/ The Rimm Lab at Yale Pathology, under the direction of David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and professor of medicine (medical oncology), marks 30 years of research, innovation, and training. Fri, 23 May 2025 04:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/new-research-presented-from-yale-cancer-center-at-aacr25/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/new-research-presented-from-yale-cancer-center-at-aacr25/ Yale Cancer Center faculty and trainees joined 22,000 cancer researchers from around the world to share the latest advances in cancer science and medicine earlier this week in Chicago for the 116th American Association for Cancer Research (AACR) annual meeting. Dr. Patricia LoRusso, Amy and Joseph Perella Professor of Medicine at Yale Cancer Center and AACR President for 2024-25, shared her global view on cancer. “Cancer is a global disease—it spares no continent, no country. And each patient that gets the disease deserves treatment.” Thu, 01 May 2025 12:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/yale-cancer-center-research-breakthroughs-unveiled-at-aacr-annual-meeting/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/yale-cancer-center-research-breakthroughs-unveiled-at-aacr-annual-meeting/ Yale Cancer Center presentations at the AACR Annual Meeting will include oral and poster presentations as well as educational sessions, showcasing cutting-edge cancer science and medicine. Mon, 21 Apr 2025 09:00:00 Z https://www.nature.com/articles/s41571-024-00984-x https://www.nature.com/articles/s41571-024-00984-x Tumour-infiltrating lymphocytes (TILs) are crucial effectors of the anticancer immune response and are hypothesized to be key determinants the efficacy of immune-checkpoint inhibitors (ICIs). Herein, the authors review studies that have evaluated the roles of various TIL subsets as predictive biomarkers for ICIs, as well as opportunities, challenges and strategies for future research in this field. Fri, 17 Jan 2025 13:45:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/public-school-students-explore-careers-at-annual-yale-pathology-day/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/public-school-students-explore-careers-at-annual-yale-pathology-day/ Chen Liu, MD, PhD, Chair of Yale Pathology, welcomes public school students to the 2nd Annual Yale Pathology Day, where they explored careers in pathology. Wed, 13 Nov 2024 05:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/study-uncovers-at-least-one-cause-of-roadblocks-to-cancer-immunotherapy/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/study-uncovers-at-least-one-cause-of-roadblocks-to-cancer-immunotherapy/ More than half of human cancers, called “non-inflamed” or “cold” tumors, are not being effectively infiltrated by the cancer-fighting T cells. Essentially, the soldiers are excluded from the battlefield. Yale Cancer Center researchers want to know why. Mon, 06 May 2024 11:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/new-advanced-diagnostic-tests-lab-to-perform-interpret-clinical-grade-molecular-testing-of-biomarkers/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/new-advanced-diagnostic-tests-lab-to-perform-interpret-clinical-grade-molecular-testing-of-biomarkers/ The Yale Advanced Diagnostic Tests Laboratory in the Department of Pathology, a new unit of Yale Pathology Laboratories, offers access to novel molecular tests to external users, performing and interpreting clinical grade and high-quality molecular analysis of human tissue samples. Tue, 28 Nov 2023 18:30:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/resistance-to-immune-checkpoint-inhibitors-in-nsclc/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/resistance-to-immune-checkpoint-inhibitors-in-nsclc/ In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell lung cancer (NSCLC). We’ll be hearing from Professor Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, Dr Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, and Dr Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, about new developments in our understanding of mechanisms of resistance, as well as possible therapeutic options for overcoming resistance. Thu, 19 Jan 2023 04:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/class-of-1961-cancer-research-awards-announced/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/class-of-1961-cancer-research-awards-announced/ Yale Cancer Center's Class of 1961 Cancer Research Awards were presented to Nikhil Joshi, PhD, and Kurt Schalper, MD, PhD, at the annual Yale Cancer Center Conclave on January 5, 2023. Wed, 11 Jan 2023 04:00:00 Z https://www.bioanalysis-zone.com/webinars/covid-19-variants-cell-and-gene-therapies-sciex-ppd/ https://www.bioanalysis-zone.com/webinars/covid-19-variants-cell-and-gene-therapies-sciex-ppd/ As the world continues to grapple with the COVID-19 pandemic, we gathered experts from different disciplines to discuss the emergence of novel variants of concern and the development of cell and gene therapies, both in the past and throughout the COVID-19 pandemic. Thu, 01 Dec 2022 05:00:00 Z https://www.vumedi.com/video/sitc-2022-tap2-deficiency-mediates-adaptive-immune-evasion-and-immunotherapy-resistance-in-human-nsc/?token=d6d4eb21-6a2e-4363-b53e-e91cd7e3f0f6&link_data=eyJiZXRfbWFpbF9pdGVtX2lkIjoxNjg1MTYzMTksImJldF9tYWlsX2FjdGlvbiI6ImJjIn0%3A1pUony%3AywUI0v_SYOzwYwBj2Q4hIV8xlRKsOJS8fW6G7qtKhgA https://www.vumedi.com/video/sitc-2022-tap2-deficiency-mediates-adaptive-immune-evasion-and-immunotherapy-resistance-in-human-nsc/?token=d6d4eb21-6a2e-4363-b53e-e91cd7e3f0f6&link_data=eyJiZXRfbWFpbF9pdGVtX2lkIjoxNjg1MTYzMTksImJldF9tYWlsX2FjdGlvbiI6ImJjIn0%3A1pUony%3AywUI0v_SYOzwYwBj2Q4hIV8xlRKsOJS8fW6G7qtKhgA TAP2 Deficiency Mediates Adaptive Immune Evasion and Immunotherapy Resistance in Human NSCLC Mon, 28 Nov 2022 05:00:00 Z https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/non-small-cell-lung-cancer-new-findings-on-a-biomarker-and-immunotherapy-resistance/ https://websites4-live-prod.ysmdevs.com/lab/schalper/news-article/non-small-cell-lung-cancer-new-findings-on-a-biomarker-and-immunotherapy-resistance/ Kishu Ranjan, PhD, of Yale University School of Medicine, discusses his study findings, which identified a deficiency in the biomarker TAP2 as a prominent immune evasion mechanism in patients whose non–small cell lung cancer has resisted immunotherapy. Fri, 11 Nov 2022 04:00:00 Z https://www.vjoncology.com/video/k6emokhrfog-potential-clinical-applications-of-tap12-downregulation-in-solid-tumors/ https://www.vjoncology.com/video/k6emokhrfog-potential-clinical-applications-of-tap12-downregulation-in-solid-tumors/ Downregulation of TAP2 and to a lesser extent, TAP1, have been found to increase immune evasion in tumors. Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, discusses the clinical implications and future research potential for these findings. Elucidating additional mutations in TAP1/2, novel molecular targets such as RBBP7 and epigenetic modulators are crucial to exploit TAP1/2 downregulation to increase PD-L1 inhibitor efficacy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA. Thu, 27 Oct 2022 04:00:00 Z https://www.univision.com/local/dallas-kuvn/de-que-trata-la-inmunoterapia-un-tratamiento-que-ha-mostrado-grandes-avances-en-la-lucha-contra-el-cancer-video https://www.univision.com/local/dallas-kuvn/de-que-trata-la-inmunoterapia-un-tratamiento-que-ha-mostrado-grandes-avances-en-la-lucha-contra-el-cancer-video Este 22 de septiembre el Instituto de Investigación del Cáncer en Estados Unidos llevará a cabo una conferencia virtual en la que abordará varios temas sobre la inmunoterapia y sus beneficios para los pacientes con cáncer. De acuerdo con Kurt Schalper, profesor de la Universidad de Yale, el objetivo de dicha reunión es lograr que la comunidad hispana tenga acceso a información valiosa acerca de dicho tratamiento. | This September 22, the Institute for Cancer Research in the United States will hold a virtual conference in which it will address various topics about immunotherapy and its benefits for cancer patients. According to Kurt Schalper, a professor at Yale University, the objective of this meeting is to ensure that the Hispanic community has access to valuable information about said treatment. Thu, 22 Sep 2022 04:00:00 Z https://www.prnewswire.com/news-releases/cancer-research-institute-to-host-second-annual-spanish-language-virtual-immunotherapy-patient-summit-moderated-by-ana-patricia-gamez-to-connect-the-us-hispanic-cancer-community-with-information-that-can-save-lives-301618148.html https://www.prnewswire.com/news-releases/cancer-research-institute-to-host-second-annual-spanish-language-virtual-immunotherapy-patient-summit-moderated-by-ana-patricia-gamez-to-connect-the-us-hispanic-cancer-community-with-information-that-can-save-lives-301618148.html The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system's power to control and potentially cure all cancers, will offer its second annual CRI Virtual Immunotherapy Patient Summit in Spanish on September 22, 2022, 2-5 p.m. ET. This free virtual event, moderated by TV Host and Entrepreneur Ana Patricia Gámez, and presented completely in Spanish, will connect Hispanic cancer patients and caregivers with groundbreaking research updates from leading immunotherapy experts driving scientific breakthroughs and advancements that impact patient care. Tue, 06 Sep 2022 04:00:00 Z